Q-omics provides the consensus-scored SSC5D profile across patient tissues and cancer cell-line models. SSC5D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SSC5D is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, SSC5D protein abundance shows 30,228 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, BLCA, and BRCA as cancer lineages where SSC5D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSC5D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSC5D survival associations across molecular data types. SSC5D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSC5D RNA expression–survival associations across cancer types. High SSC5D expression shows unfavorable associations in MESO, KIRC, LGG, BLCA, THCA and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SSC5D RNA expression.
This table summarizes SSC5D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SSC5D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSC5D shows lower tumor expression in BLCA, UCEC, KICH, COAD and LIHC and higher tumor expression in HNSC. The BLCA box plot shows higher SSC5D RNA expression in normal versus tumor tissue (log2 FC = −2.807, t-test p < 0.001).
This table shows molecular features associated with SSC5D in patient tissues and cancer cell lines. In patient samples, SSC5D shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SSC5D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
